Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Shares Take a Hit

Shares in Invitrogen tumbled 14.44 percent for the tracking period ended Tuesday, leading all decliners in the BCW Index this week. The firm missed Wall Street and internal targets for its third quarter at its BioReliance business continues to struggle (see article in this week's issue). Bruker also had a tough week, with its shares dropping 7.43 percent on the heels of its agreement to acquire an X-ray microanalysis business. On the other end of the spectrum, Molecular Devices gained 15.47 percent after reporting a third-quarter profit and 9-percent revenue growth for the third quarter. Shares in Applied Biosystems and PerkinElmer also posted strong gains during the past week. Overall, the BCW Index declined .9 percent, compared to a .3-percent increase for the Dow Jones Industrial Average, the Nasdaq inched up .2 percent, and the Nasdaq Biotech Index lost 1.7 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Nov. 1, 2005)
Last Price
(Oct. 25, 2005)
% change
Agilent
A
32.13
31.18
3.05
Applied Biosystems
ABI
24.97
23.35
6.94
Beckman
BEC
49.5
50.47
-1.92
Bio-Rad
BIO
57.26
55.57
3.04
Bruker
BRKR
4.11
4.44
-7.43
Fisher Scientific
FSH
56.64
58.16
-2.61
GE
GE
33.6
33.91
-0.91
Harvard Bio
HBIO
3.17
3.12
1.60
Invitrogen
IVGN
63.47
74.18
-14.44
Molecular Devices
MDCC
22.91
19.84
15.47
PerkinElmer
PKI
22.1
20.82
6.15
Qiagen
QGEN
11.92
11.86
0.51
Sigma
SIAL
64.06
63.53
0.83
Stratagene
STGN
9.69
9.87
-1.82
Thermo
TMO
29.75
30.7
-3.09
Waters
WAT
36.51
35.75
2.13
BCW Index Average
32.61
32.92
-0.94
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.